C12Y 306/04004
Plus-end-directed kinesin atpase
Official title: Plus-end-directed kinesin ATPase (3.6.4.4)
C12Y306/04004 (Plus-end-directed kinesin atpase) appears on 18 US grants and 19 published applications in this corpus.
Search patents in C12Y- Granted patents
- 18
- Published applications
- 19
- Assignees
- 8
- Inventors
- 24
- Latest grant
- 15 Oct 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 1 |
| 2015 | 1 | 2 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 3 | 2 |
| 2019 | 1 | 2 |
| 2020 | 4 | 5 |
| 2021 | 5 | 3 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 0 |
By publication year.
Recent patents
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)15 Oct 2024US 12,116,574 B2Northwestern University
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (KLC1C)14 Sep 2021US 11,118,180 B2Northwestern University
- Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing8 Jun 2021US 11,028,391 B2Albert Einstein College of Medicine
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)23 Feb 2021US 10,925,949 B2Immatics Biotechnologies GmbH
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)26 Jan 2021US 10,898,562 B1Immatics Biotechnologies GmbH
- Anti-inflammatory treatment via inhibition of endothelial cell kinesin light chain 1, variant 1 (klc1c)18 Aug 2022US 2022/0259591 A1Northwestern University
- Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing4 Nov 2021US 2021/0340541 A1Albert Einstein College of Medicine
- Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)28 Jan 2021US 2021/0023189 A1Immatics Biotechnologies GmbH
- Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)14 Jan 2021US 2021/0008189 A1Immatics Biotechnologies GmbH
- Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing3 Sep 2020US 2020/0277602 A1Albert Einstein College of Medicine
Most cited
By later US patents
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)25US 10,286,052 B2Immatics Biotechnologies GmbH · 2019
- Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)24US 10,064,924 B2Immatics Biotechnologies GmbH · 2018
- Method of preventing transport of a neurotropic virus and identifying agents for achieving same5US 6,953,661 B1The University of Sydney · 2005
- Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing3US 10,087,446 B2Albert Einstein College of Medicine · 2018
- Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing3US 9,994,845 B2Albert Einstein College of Medicine · 2018